"10.1371_journal.pone.0148057","plos one","2016-02-09T00:00:00Z","Holger Reinecke; Günter Breithardt; Christiane Engelbertz; Roland E Schmieder; Manfred Fobker; Hans O Pinnschmidt; Boris Schmitz; Philipp Bruland; Karl Wegscheider; Hermann Pavenstädt; Eva Brand","Division of Vascular Medicine, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany; Department of Nephrology, Hypertension, and Rheumatology, University Hospital Muenster, Muenster, Germany; Department of Nephrology and Hypertension, University of Erlangen-Nuernberg, Erlangen, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Muenster, Muenster, Germany; Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Muenster, Muenster, Germany; Institute of Medical Informatics, University of Muenster, Muenster, Germany","Analyzed the data: HOP KW. Wrote the paper: HR GB CE EB. Conception and design of the CAD-REF registry: EB GB HP HR RES. Collection and assembly of data: EB GB HP HR RES. Analysis of human material: MF. Analysis, interpretation and critical revision: HR GB CE RES MF HOP BS PB KW HP EB.","The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Holger Reinecke has received speaker honoraria from Sanofi-Aventis, Daiichi-Sankyo, The Medicine Company, Cordis, and Novartis. He has acted as a consultant for BMS and Pluristem. He took part in the conduction of multicenter trials of BARD, Bayer, BIOTRONIK, and Pluristem. Günter Breithardt has received research grants for his institution from 3M, Sanofi-Aventis, St. Jude, honoraria from Sanofi-Aventis, Boehringer Ingelheim, Boston Scientific, Bayer Health Care, BMS/Pfizer (all of modest degree), and has been on the following advisory boards: Sanofi-Aventis, Boehringer Ingelheim, Boston Scientific, Bayer Health Care, BMS/Pfizer, MSD, Otsuka Pharma. Roland E. Schmieder is a member of the speakers’ bureau; he has received honoraria from AstraZeneca, Berlin Chemie AG, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Medtronic, Novartis, Servier, Takeda Pharmaceuticals and Terumo. He has acted as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Medtronic, Novartis and Servier, and has received grant or research support (awarded to the University Hospital, University Erlangen/Nürnberg) from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Novartis and Medtronic. Karl Wegscheider has received consulting fees/honoraria from Biotronik, Medtronik, Merck, Resmed, Takeda. Hermann Pavenstädt has received speaker honoraria from Novartis and Merck KGaA. Eva Brand has received speaker honoraria from Sanofi-Aventis, Daiichi-Sankyo, and Novartis. All other authors declare that they have no conflicting interests and no financial disclosures with regard to this publication and the presented results. Research grants for the CAD-REF Registry were given by Amgen GmbH, Munich (https://www.amgen.de/), AstraZeneca GmbH, Wedel (http://www.astrazeneca.de/willkommen), Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein (http://www.boehringer-ingelheim.de/), and Sanofi-Aventis Deutschland GmbH, Frankfurt (http://www.sanofi.de/l/de/de/index.jsp). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2016","02","Holger Reinecke","HR",11,TRUE,NA,NA,2,4,TRUE,FALSE,FALSE,0,NA,FALSE
